701979-43-3Relevant academic research and scientific papers
Design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compounds as PPARα selective activators
Li, Zhibin,Liao, Chenzhong,Ko, Ben C. B.,Shan, Song,Tong, Edith H. Y.,Yin, Zihui,Pan, Desi,Wong, Vincent K. W.,Shi, Leming,Ning, Zhi-Qiang,Hu, Weiming,Zhou, Jiaju,Chung, Stephen S. M.,Lu, Xian-Ping
, p. 3507 - 3511 (2007/10/03)
Lipid accumulation in nonadipose tissues is increasingly linked to the development of type 2 diabetes in obese individuals. We report here the design, synthesis, and evaluation of a series of novel PPARα selective activators containing 1,3-dicarbonyl moie
NONCYCLIC 1,3-DICARBONYL COMPOUNDS AS DUAL PPAR AGONISTS WITH POTENT ANTIHYPERGLYCEMIC AND ANTIHYPERLIPIDEMIC ACTIVITY
-
Page 23, (2008/06/13)
Disclosed are the preparation and pharmaceutical use of novel noncyclic 1,3-dicarbonyl compounds of formula I, wherein ring A, ring B, R', R2, R3, R4, R5, X, Y, Z, Q, Ar and n are as defined in the specification. These compounds, as peroxisome proliferator-activated receptor (PPAR) dual agonists for both RXR/PPARgamma and RXRIPPARalpha heterodimers, are useful in the treatment and/or prevention of type 2 diabetes and associated metabolic syndrome such as hypertension, obesity, insulin resistance, hyperlipidemia, hyperglycemia, hypercholesterolemia, atherosclerosis, coronary artery disease, and other cardiovascular disorders.
